Potentially Reverse the Progression

Aquinnah Pharmaceuticals

CAMBRIDGE, Mass. — May 15, 2018 — Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neurodegenerative therapeutics, announced today that it has been awarded $3.4 million from the National Institute of Neurological Disorders and Stroke (NINDS) in a competing grant to advance novel therapeutic drug candidates towards the clinic for treating patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

More info

Leave a Reply

Your email address will not be published. Required fields are marked *